Boston Scientific and Bard announce distribution agreement for Lutonix


Boston Scientific will now distribute the Lutonix 035 drug-coated balloon in the USA under a limited distribution agreement reached with Bard. Terms of the agreement were not disclosed.

Lutonix is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel that is designed to decrease the incidence of restenosis and improve patency in patients with stenosed femoropopliteal vessels, often seen with peripheral artery disease. Lutonix drug-coated balloon was the first Food and Drug Administration-approved drug-coated balloon in the USA.

“Drug-coated balloons are a growing part of the treatment algorithm for peripheral artery disease and provide an alternative in the event a physician chooses not to place a permanent implant or scaffold,” said Jeff Mirviss, president of Peripheral Interventions, Boston Scientific. “We believe Bard’s Lutonix drug-coated balloon is a great addition to our broad portfolio of vascular products.”

“This agreement is designed to expand the reach of the Lutonix drug-coated balloon and will afford more patients suffering from peripheral artery disease an opportunity to benefit from this innovative technology and clinically-proven therapy,” said Steve Williamson, president of Bard Peripheral Vascular, one of Bard’s subsidiaries.